Combivent
WikiDoc Resources for Combivent |
Articles |
---|
Most recent articles on Combivent |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Combivent at Clinical Trials.gov Clinical Trials on Combivent at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Combivent
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Combivent Discussion groups on Combivent Directions to Hospitals Treating Combivent Risk calculators and risk factors for Combivent
|
Healthcare Provider Resources |
Causes & Risk Factors for Combivent |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Synonyms / Brand Names: Ipratropium Bromide + Salbutamol Sulfate, Ipratropium/Salbutamol, Combivent Inhalation Aerosol, Combivent Inhalation Solution
Dosing and Administration
The dose of Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol is two inhalations four times a day. Patients may take additional inhalations as required; however, the total number of inhalations should not exceed 12 in 24 hours. Safety and efficacy of additional doses of Combivent Inhalation Aerosol beyond 12 puffs/24 hours have not been studied. Also, safety and efficacy of extra doses of ipratropium or albuterol in addition to the recommended doses of Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol have not been studied. It is recommended to “test-spray” three times before using for the first time and in cases where the aerosol has not been used for more than 24 hours. Avoid spraying into eyes.
Adapted from the FDA Package Insert. Template:WH